Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
102 participants
INTERVENTIONAL
2014-05-14
2014-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: BMS-663068 + Rifabutin
Regimen A: BMS-663068 tablet by mouth as specified
Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified
BMS-663068
BMS-663068
Rifabutin
Rifabutin
Cohort 2: BMS-663068 + Rifabutin + Ritonavir
Regimen A: BMS-663068 tablet by mouth as specified
Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified
BMS-663068
BMS-663068
Rifabutin
Rifabutin
Ritonavir
Ritonavir
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-663068
BMS-663068
Rifabutin
Rifabutin
Ritonavir
Ritonavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
a) Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's Institutional Review Board (IRB) or Independent Ethics Committee (IEC) before the initiation of any protocol-required procedures
2. Target Population
* a) Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, 12-lead ECG measurements, and clinical laboratory test results
* b) Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive BMI = weight (kg)/\[height (m)\]2
* c) Subject Reenrollment: This study permits the reenrollment of a subject that has discontinued the study as a pretreatment failure (ie, subject has not been randomized/has not been dosed). If reenrolled, the subject must be reconsented
3. Age and Reproductive Status
* a) Men and women, ages 18 to 50 years, inclusive
* b) Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study drug
* c) Women must not be breastfeeding
* d) WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of Rifabutin (13 days) plus 30 days (duration of ovulatory cycle) for a total of 43 days posttreatment completion
* e) Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of Rifabutin (13 days) plus 90 days (duration of sperm turnover) for a total of 103 days posttreatment completion
Exclusion Criteria
* a) Any significant acute or chronic medical illness as determined by the Investigator.
* b) Current or recent (within 3 months of study drug administration) gastrointestinal disease
* c) Any major surgery within 4 weeks of study drug administration
* d) Any gastrointestinal surgery that could impact upon the absorption of study drug
* e) Intractable diarrhea (≥6 loose stools per day for at least 7 consecutive days) within 30 days prior to the first dose of study drug
* f) History of acute or chronic pancreatitis
* g) History of active or latent tuberculosis or any recent exposure to someone with tuberculosis
* h) History of uveitis and/or current eye or vision problems with the exception of corrective lenses
* i) Contact lens use during study drug administration or the need for contact lenses during study drug administration
* j) Donation of blood to a blood bank or in a clinical study (except screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma donation only)
* k) Blood transfusion within 4 weeks of study drug administration.
* l) History of any hemolytic disorders, including drug-induced hemolysis.
* m) Inability to tolerate oral medication
* n) Inability to be venipunctured and/or tolerate venous access
* o) Recent (within 6 months of study drug administration) history of smoking or current smokers
* p) Recent (within 6 months of study drug administration) drug or alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), Diagnostic Criteria for Drug and Alcohol Abuse
* q) Any other sound medical, psychiatric, and/or social reason as determined by the Investigator
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
ViiV Healthcare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI438-041
Identifier Type: OTHER
Identifier Source: secondary_id
206282
Identifier Type: -
Identifier Source: org_study_id